A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects
Open Access
- 1 August 2021
- journal article
- research article
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 69, 102051
Abstract
No abstract availableKeywords
Funding Information
- Genentech Inc
This publication has 20 references indexed in Scilit:
- Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18–64 years oldEuropean Respiratory Journal, 2016
- Idiopathic Pulmonary Fibrosis: Evolving ConceptsMayo Clinic Proceedings, 2014
- Beyond the diagnosis of idiopathic pulmonary fibrosis; the growing role of systems biology and stratified medicineCurrent Opinion in Pulmonary Medicine, 2013
- Idiopathic Pulmonary FibrosisSeminars in Respiratory and Critical Care Medicine, 2012
- Pulmonary fibrosis: patterns and perpetratorsJournal of Clinical Investigation, 2012
- Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biologyEuropean Respiratory Journal, 2010
- Strategies for treating idiopathic pulmonary fibrosisNature Reviews Drug Discovery, 2010
- Cellular and molecular mechanisms of fibrosisThe Journal of Pathology, 2007
- Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2001
- Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for TherapyAnnals of Internal Medicine, 2001